Evidence map›Paper›PMID 1526330›Full record

ReviewDiabetes1992

Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus.

M R Taskinen

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Diabetes, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02045290 (Metformin Therapy for Overweight Adolescents With Type 1 Diabetes), which is not on this map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02045290 phase3completedstarted 2014, after this paper: background citation

Metformin Therapy for Overweight Adolescents With Type 1 Diabetes (T1D)--Insulin Clamp Ancillary Study for Assessment of Insulin Resistance

Ran2014Enrolled37Registered outcomes3Posted comparisons0ConditionsType 1 DiabetesArmsMetformin, Placebo
PMID 15855566PMID 13833973PMID 1443555PMID 14514347PMID 14514603PMID 14747240PMID 14988302PMID 15211099PMID 15467773PMID 15677783PMID 15699257PMID 15983263other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 175 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. International scholarly research notices · 2017
    Article
  10. Review
  11. Review
  12. Regulation of signal transduction by HDL.Journal of lipid research · 2013
    Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Treatment approaches for diabetes and dyslipidemia.Hormone research in paediatrics · 2011
    Review
  20. Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function.The Journal of clinical endocrinology and metabolism · 2010 · on this map
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

M R TaskinenIII Department of Medicine, University of Helsinki, Finland.
University of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In people with diabetes, the concentration of an individual lipoprotein or apolipoprotein can be highly variable and is totally different in the two major forms of the disease. Alterations in the concentrations of major lipids and lipoproteins are well characterized in both IDDM and NIDDM. In general, the lipoprotein pattern is antiatherogenic in individuals with IDDM who are treated and have optimal glycemic control. In contrast, NIDDM is associated with atherogenic changes of serum lipids and lipoproteins regardless of the mode of treatment. In people with both types of diabetes, the distribution of apoE phenotype seems to be similar to that in nondiabetic populations. IDDM patients with microalbuminuria show atherogenic changes of lipoproteins and have elevated levels of Lp(a), which is a risk factor of coronary artery disease. Whether glycemic control influences the concentration of Lp(a) is still an open question. An important issue is that the concentration of a lipoprotein can be normal without excluding compositional abnormalities that are potentially atherogenic. Such alterations are present in people with both IDDM and NIDDM. Consequently, it has been questioned whether the target values to start treatment should be lower in diabetic than in nondiabetic populations.

Indexed as

Diabetes ComplicationsDiabetes MellitusDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2HumansHyperlipidemiasLipoproteinsPrevalenceLipoproteins

Identifiers

PMID1526330
OpenAlexW2008965204

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.